Daiichi Life Insurance Co. Ltd. bought a new position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 14,741 shares of the company’s stock, valued at approximately $2,484,000.
Other large investors have also made changes to their positions in the company. Commerce Bank bought a new stake in shares of Neurocrine Biosciences in the 2nd quarter valued at approximately $2,233,000. Northwestern Mutual Wealth Management Co. acquired a new stake in shares of Neurocrine Biosciences in the second quarter worth $152,000. Evolve Private Wealth LLC bought a new stake in Neurocrine Biosciences during the second quarter valued at about $849,000. Landscape Capital Management L.L.C. acquired a new stake in Neurocrine Biosciences in the 2nd quarter valued at approximately $1,621,000. Finally, Korea Investment CORP acquired a new stake in shares of Neurocrine Biosciences in the second quarter worth $29,155,000. Institutional investors own 92.59% of the company’s stock.
Insiders Place Their Bets
In related news, insider Darin Lippoldt sold 10,000 shares of the company’s stock in a transaction dated Thursday, July 9th. The shares were sold at an average price of $179.60, for a total transaction of $1,796,000.00. Following the transaction, the insider owned 54,729 shares in the company, valued at $9,829,328.40. This represents a 15.45% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Stephen A. Sherwin sold 25,000 shares of the stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $165.32, for a total transaction of $4,133,000.00. Following the sale, the director directly owned 15,860 shares in the company, valued at approximately $2,621,975.20. This represents a 61.18% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 131,524 shares of company stock worth $21,668,924 over the last ninety days. Company insiders own 4.60% of the company’s stock.
Analyst Ratings Changes
Neurocrine Biosciences Price Performance
Shares of NBIX opened at $152.57 on Monday. The company has a market capitalization of $15.51 billion, a P/E ratio of 22.37, a PEG ratio of 0.71 and a beta of 0.39. Neurocrine Biosciences, Inc. has a one year low of $122.14 and a one year high of $186.12. The business’s 50 day simple moving average is $167.14 and its 200-day simple moving average is $148.96.
Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) last released its quarterly earnings results on Friday, July 31st. The company reported $2.85 earnings per share for the quarter, beating analysts’ consensus estimates of $1.65 by $1.20. Neurocrine Biosciences had a return on equity of 22.43% and a net margin of 20.91%.The firm had revenue of $959.00 million during the quarter, compared to analysts’ expectations of $891.16 million. During the same period last year, the firm posted $1.65 EPS. The business’s revenue was up 39.5% on a year-over-year basis. On average, sell-side analysts anticipate that Neurocrine Biosciences, Inc. will post 7.25 EPS for the current fiscal year.
Neurocrine Biosciences Company Profile
Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.
The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.
Read More
- Five stocks we like better than Neurocrine Biosciences
- VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You?
- 3 Closed-End Funds to Maximize Dividend Payments
- Rocket Lab’s Sell-Off Is Fading—Is It Finally Safe to Buy?
- $27 Billion in Buybacks: 3 Stocks Betting Their Strong Runs Aren’t Over
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
